Abstract 364P
Background
To develop artificial intelligence auto-segmentation model that generates consistent, high-quality lymph nodes contouring in head and neck cancer patients who received radiotherapy.
Methods
There were 60 computed tomography (CT) scans were retrospectively selected into training and another 60 CT scans were collected into cross-validation. All target delineations covered head and neck lymph node level I through V and based on the Radiation Therapy Oncology Group (RTOG) guideline. All targets were approved by radiation oncologists specializing in head and neck cancer. The volume of interest and all approved contours were used to train a 3D U-Net model. Different lymph node levels were trained independently. The trained model was used on cross-validation group. Auto-segmentations were revised by 2 radiation oncologists.
Results
The Dice Similarity Coefficients were 0.79 and 0.88 in trained group and cross-validation group. The volume changes ranged from -22.2 to 89.0 cm3. The center shift for x-direction, y-direction, and z-direction were -0.57 to 0.16 cm, -0.14 to 0.88 cm, and -0.19 to 0.38 cm, respectively.
Conclusions
We developed an artificial intelligence auto-segmentation model to autodelineate head and neck lymph nodes. Most results of auto-segmentations were acceptable after radiation oncologist review. This enables more efficient and consistent targeting of neck lymph nodes in radiation treatment planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract